Who are Rescue Medication: Self-Injectable Epinephrine's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): VIBEGRON, Striverdi Respimat, Breo Ellipta, Myrbetriq, Arcapta Neohaler, Brovana.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/rescue-medication-self-injectable-epinephrine.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Rescue Medication: Self-Injectable Epinephrine — Competitive Intelligence Brief

Rescue Medication: Self-Injectable Epinephrine (Rescue Medication: Self-Injectable Epinephrine) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Sympathomimetic amine; Adrenergic agonist. Area: Immunology; Allergy/Anaphylaxis.

phase 3 Sympathomimetic amine; Adrenergic agonist Alpha-1 adrenergic receptor; Beta-2 adrenergic receptor Immunology; Allergy/Anaphylaxis Small molecule Live · refreshed every 30 min

Target snapshot

Rescue Medication: Self-Injectable Epinephrine (Rescue Medication: Self-Injectable Epinephrine) — ALK-Abelló A/S. Epinephrine is a sympathomimetic amine that binds to alpha and beta adrenergic receptors to rapidly reverse the symptoms of anaphylaxis by increasing blood pressure, improving airway patency, and reducing allergic mediator release.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Rescue Medication: Self-Injectable Epinephrine TARGET	Rescue Medication: Self-Injectable Epinephrine	ALK-Abelló A/S	phase 3	Sympathomimetic amine; Adrenergic agonist	Alpha-1 adrenergic receptor; Beta-2 adrenergic receptor
VIBEGRON	VIBEGRON		marketed	beta3-Adrenergic Agonist [EPC]		2018-01-01
Striverdi Respimat	OLODATEROL	Boehringer Ingelheim	marketed	beta2-Adrenergic Agonist	Beta-2 adrenergic receptor	2014-01-01
Breo Ellipta	VILANTEROL	Glaxo Grp Ltd	marketed	beta2-Adrenergic Agonist	Beta-2 adrenergic receptor	2013-01-01
Myrbetriq	MIRABEGRON	Apgdi	marketed	beta3-Adrenergic Agonist [EPC]	Beta-3 adrenergic receptor	2012-01-01
Arcapta Neohaler	INDACATEROL	Novartis	marketed	beta2-Adrenergic Agonist	Beta-2 adrenergic receptor	2011-01-01
Brovana	ARFORMOTEROL	Lupin	marketed	beta2-Adrenergic Agonist	Beta-2 adrenergic receptor	2006-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

2027-06-14 — Breo Ellipta · 8511304 · US
2027-10-02 — Breo Ellipta · 9333310 · US
2027-10-23 — Breo Ellipta · 8113199 · US
2027-12-14 — Breo Ellipta · 8511304*PED · US
2027-12-18 — Breo Ellipta · 7488827 · US
2028-02-05 — Breo Ellipta · 8161968 · US
2028-04-02 — Breo Ellipta · 9333310*PED · US
2028-04-23 — Breo Ellipta · 8113199*PED · US
2028-08-05 — Breo Ellipta · 8161968*PED · US
2029-02-26 — Breo Ellipta · 11116721 · US
2029-08-26 — Breo Ellipta · 11116721*PED · US
2030-03-08 — Breo Ellipta · 8534281 · US
2030-09-08 — Breo Ellipta · 8534281*PED · US
2030-10-11 — Breo Ellipta · 8746242 · US
2030-11-29 — Breo Ellipta · 9750726 · US
2030-11-29 — Breo Ellipta · 11090294 · US
2031-04-11 — Breo Ellipta · 8746242*PED · US

Sponsor landscape (Sympathomimetic amine; Adrenergic agonist class)

ALK-Abelló A/S · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Rescue Medication: Self-Injectable Epinephrine — Competitive Intelligence Brief. https://druglandscape.com/ci/rescue-medication-self-injectable-epinephrine. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab